Key Takeaways Globus Medical gains from U.S. Spine growth and 35% y/y rise in core trauma business.GMED's recent Nevro deal expands market reach, unlocking a $2.5B musculoskeletal opportunity.New product launches like DuraPro and Verzera highlight GMED's R&D focus.Globus Medical, Inc. (GMED) continues to benefit from the robust demand for its Musculoskeletal Solutions products. Additionally, its string of product launches is highly promising to drive growth in the coming quarters. Meanwhile, headwinds from ...

Company Developments - Globus Medical, Inc. (GMED) has launched DuraPro, a next-generation oscillating system with Excelsius navigation capabilities, aimed at enhancing procedural workflows through improved safety and efficiency [1][8] - The company has introduced 18 new products in 2024, including the ExcelsiusHub and ExcelsiusFlex surgical navigation systems, and expanded its Advanced Materials Science implant portfolio with the COHERE ALIF Spacer in Q1 2025 [3] - The DuraPro system features advanced oscillating technology that prevents soft tissue wrapping and allows for accurate bone removal while protecting delicate tissue [5][8] - GMED has also launched Verzera, a navigated high-speed drill system that integrates with ExcelsiusGPS and ExcelsiusHub, enhancing surgical workflows [6] Financial Performance and Market Outlook - GMED has a market capitalization of $7.56 billion, with 2025 revenue expected to rise by 12.8% year over year according to the Zacks Consensus Estimate [4] - The company has delivered an average earnings surprise of 10.1% over the trailing four quarters [4] - Despite recent product launches, GMED shares have declined by 23.2% over the past year, compared to a 13.7% decline in the industry [11] Industry Trends - The global high-speed surgical drill market is projected to grow from $2.44 billion in 2025 at a compound annual growth rate of 7.8% from 2025 to 2033, driven by the rise in minimally invasive surgical procedures and technological advancements [9]

Globus Medical, Inc. (GMED) reported first-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which missed the Zacks Consensus Estimate by 8.1%. The figure increased 7.9% year over year. Net sales generated in the United States increased 0.2% year over year (same at CER) to $483.9 million, which missed our model's projection of $519.2 million. Across international markets, revenues decreased 7.7% (down 4.6% at CER) to $114.3 million, which also missed our model estimate of $124.6 million. GMED's Pr ...